Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: The male and female genital tract

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1149-1167

  Else, Laura J ^a   Taylor, Stephen ^b   Back, David J ^a   Khoo, Saye H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TRANSPORT; FEMALE GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE GENITAL SYSTEM; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; SEMINAL PLASMA; SEX DIFFERENCE; UTERINE CERVIX CYTOLOGY;

ADULT; ANTI-HIV AGENTS; BODY FLUIDS; CAPILLARY PERMEABILITY; FEMALE; GENITALIA, FEMALE; GENITALIA, MALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; ORGAN SPECIFICITY; REVERSE TRANSCRIPTASE INHIBITORS; SEMEN; SEX FACTORS; VIRAL LOAD; VIRUS REPLICATION;

EID: 83455179327     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1919     Document Type: Review

References (135)

1. Palella FJ, Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)
2. Benzie AA, Bansi LK, Sabin CA, et al. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007; 21:1423-1430. (Pubitemid 46988002)
3. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3:215-220. (Pubitemid 29047912)
4. de Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42:599-605. (Pubitemid 36805618)
5. Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002; 46:2926-2932.
6. Duval X, Mentre F, Lamotte C, et al. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort. Ther Drug Monit 2005; 27:63-70. (Pubitemid 40189976)
7. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188. (Pubitemid 27209433)
8. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-13197. (Pubitemid 27518498)
9. Eron JJ, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998; 12:F181-F189. (Pubitemid 28479268)
10. Hoetelmans RM. Sanctuary sites in HIV-1 infection. Antivir Ther 1998; 3 Suppl 4:13-17. (Pubitemid 28562923)
11. Mayer KH, Boswell S, Goldstein R, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999; 28:1252-1259. (Pubitemid 29272799)
12. Günthard HF, Havlir DV, Fiscus S, et al. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001; 183:1318-1327. (Pubitemid 32337113)
13. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-814. (Pubitemid 44223104)
14. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007; 21:1309-1315. (Pubitemid 46883485)
15. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
16. Kotler DP, Shimada T, Snow G, et al. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis. AIDS 1998; 12:597-604. (Pubitemid 28162098)
17. Pereira AS, Kashuba AD, Fiscus SA, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis 1999; 180:2039-2043.
18. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421. (Pubitemid 30182438)
19. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14:117-121. (Pubitemid 30116436)
20. Ghosn J, Viard JP, Katlama C, et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 2004; 18:447-457. (Pubitemid 38365872)
21. Diem K, Nickle DC, Motoshige A, et al. Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). AIDS Res Hum Retroviruses 2008; 24:561-571. (Pubitemid 351571032)
22. Liuzzi G, Chirianni A, Zaccarelli M, et al. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay. In Vivo 2004; 18:509-512. (Pubitemid 39200000)
23. Ellerbrock TV, Lennox JL, Clancy KA, et al. Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis 2001; 184:28-36. (Pubitemid 32568497)
24. Tirado G, Jove G, Kumar R, et al. Differential virus evolution in blood and genital tract of HIV-infected females: evidence for the involvement of drug and non-drug resistance-associated mutations. Virology 2004; 324:577-586. (Pubitemid 38797873)
25. Pasquier C, Saune K, Raymond S, et al. Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J Clin Microbiol 2009; 47:2883-2887.
26. Sheth PM, Kovacs C, Kemal KS, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009; 23:2050-2054.
27. Marcelin AG, Tubiana R, Lambert-Niclot S, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS 2008; 22:1677-1679.
28. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21:501-507.
29. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:38-42. (Pubitemid 46052218)
30. Taylor S, Davies S. Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:335-343.
31. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601. (Pubitemid 351650540)
32. Malmborg AS. Antimicrobial drugs in human seminal plasma. J Antimicrob Chemother 1978; 4:483-485. (Pubitemid 9053769)
33. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43:1817-1826. (Pubitemid 29395171)
34. Ndovi TT, Parsons T, Choi L, Caffo B, Rohde C, Hendrix CW. A new method to estimate quantitatively seminal vesicle and prostate gland contributions to ejaculate. Br J Clin Pharmacol 2007; 63:404-420. (Pubitemid 46426637)
35. Taylor S, Back DJ, Workman J, et al. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 1999; 13:859-860. (Pubitemid 29224590)
36. Anderson PL, Noormohamed SE, Henry K, Brundage RC, Balfour HH, Jr., Fletcher CV. Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. Pharmacotherapy 2000; 20:917-922. (Pubitemid 30659788)
37. Taylor S, van Heeswijk RP, Hoetelmans RM, et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 2000; 14:1979-1984.
38. van Praag RM, Repping S, de Vries JW, Lange JM, Hoetelmans RM, Prins JM. Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. Antimicrob Agents Chemother 2001; 45:2902-2907. (Pubitemid 32906690)
39. Reddy YS, Gotzkowsky SK, Eron JJ, et al. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J Infect Dis 2002; 186:1339-1343. (Pubitemid 35193014)
40. Cao YJ, Hendrix CW. Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment. Clin Pharmacol Ther 2008; 83:401-412. (Pubitemid 351272639)
41. Cao YJ, Ndovi TT, Parsons TL, Guidos AM, Caffo B, Hendrix CW. Effect of semen sampling frequency on seminal antiretroviral drug concentration. Clin Pharmacol Ther 2008; 83:848-856. (Pubitemid 351704914)
42. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:238-243. (Pubitemid 36070370)
43. Lafeuillade A, Solas C, Chadapaud S, Hittinger G, Poggi C, Lacarelle B. HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen. J Acquir Immune Defic Syndr 2003; 32:462-464. (Pubitemid 36363162)
44. Chaudry NI, Eron JJ, Naderer OJ, et al. Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. Clin Infect Dis 2002; 35:760-762. (Pubitemid 35024739)
45. Isaac A, Taylor S, Cane P, et al. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother 2004; 54:498-502. (Pubitemid 39177476)
46. Vergara TR, Estrela RC, Suarez-Kurtz G, Schechter M, Cerbino-Neto J, Barroso PF. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil. Ther Drug Monit 2006; 28:175-179. (Pubitemid 44314945)
47. van Leeuwen E, Ter Heine R, van der Veen F, Repping S, Beijnen JH, Prins JM. Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother 2007; 51:335-337. (Pubitemid 46047724)
48. Vourvahis M, Tappouni HL, Patterson KB, et al. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr 2008; 47:329-333. (Pubitemid 351619418)
49. Pereira AS, Kenney KB, Cohen MS, et al. Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 742:173-183. (Pubitemid 30330935)
50. Pereira AS, Kenney KB, Cohen MS, Eron JJ, Tidwell RR, Dunn JA. Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766:307-317. (Pubitemid 34142363)
51. Huang Y, Zurlinden E, Lin E, et al. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous determination of didanosine and stavudine in human plasma, bronchoalveolar lavage fluid, alveolar cells, peripheral blood mononuclear cells, seminal plasma, cerebrospinal fluid and tonsil tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 799:51-61. (Pubitemid 37500862)
52. Dumond JB, Reddy YS, Troiani L, et al. Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr 2008; 48:156-162.
53. Estrela RC, Ribeiro FS, Seixas BV, Suarez-Kurtz G. Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection. Rapid Commun Mass Spectrom 2008; 22:657-664. (Pubitemid 351373945)
54. Avery LB, Parsons TL, Meyers DJ, Hubbard WC. A highly sensitive ultra performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) technique for quantitation of protein free and bound efavirenz (EFV) in human seminal and blood plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:3217-3224.
55. Henry K, Chinnock BJ, Quinn RP, Fletcher CV, de Miranda P, Balfour HH, Jr. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 1988; 259:3023-3026.
56. Pereira AS, Smeaton LM, Gerber JG, et al. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). J Infect Dis 2002; 186:198-204. (Pubitemid 34765507)
57. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004; 18:1958-1961. (Pubitemid 39313214)
58. van Praag RM, van Heeswijk RP, Jurriaans S, Lange JM, Hoetelmans RM, Prins JM. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin Infect Dis 2001; 33:e91-e92.
59. Foster RH, Faulds D. Abacavir. Drugs 1998; 55:729-736.
60. Taylor S, Phillay D, Veldkamp A, et al. Abacavir and lamivudine reach high concentrations in the semen of HIV-1-infected men. 6th International Congress on Drug Therapy in HIV-Infection. 17-21 November 2002, Glasgow, UK. Abstract P168.
61. Fletcher CV, Kawle SP, Kakuda TN, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000; 14:2137-2144.
62. Barry MG, Khoo SH, Veal GJ, et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 1996; 10:1361-1367. (Pubitemid 26333934)
63. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269:12633-12638.
64. Stein DS, Moore KH. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 2001; 21:11-34. (Pubitemid 32047574)
65. Robbins BL, Wilcox CK, Fridland A, Rodman JH. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003; 23:695-701. (Pubitemid 36629072)
66. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42:612-617. (Pubitemid 28114817)
67. la Porte CJL, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Reviews in Antiviral Therapy 2006; 3:4-14.
68. Chan DJ, Ray JE, McNally L, Batterham M, Smith DE. Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs. Curr HIV Res 2008; 6:477-484.
69. Taylor S, Reynolds H, Sabin CA, et al. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS 2001; 15:2051-2053. (Pubitemid 32980652)
70. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75. (Pubitemid 32055781)
71. van Praag RM, Weverling GJ, Portegies P, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000; 14:1187-1194. (Pubitemid 30420662)
72. Taylor S, Back DJ, Drake SM, et al. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother 2001; 48:351-354. (Pubitemid 32898804)
73. Ghosn J, Chaix ML, Peytavin G, et al. Absence of HIV-1 shedding in male genital tract after 1 year of firstline lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J Antimicrob Chemother 2008; 61:1344-1347. (Pubitemid 351753606)
74. Lowe SH, Wensing AM, Droste JA, et al. No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations. HIV Clin Trials 2006; 7:285-290. (Pubitemid 46164963)
75. Taylor S, Boffito M, Vernazza PL. Antiretroviral therapy to reduce the sexual transmission of HIV. J HIV Ther 2003; 8:55-66.
76. de Cassia Estrela R, Ribeiro FS, Barroso PF, et al. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics 2009; 10:311-318.
77. Sankatsing SU, Droste J, Burger D, et al. Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. AIDS 2002; 16:1698-1700. (Pubitemid 34921122)
78. Taylor S, Jayasuriya AN, Berry A, et al. Darunavir concentrations exceed the protein-corrected EC for wild-type HIV in the semen of HIV-1-infected men. AIDS 2010; 24:2583-2587.
79. Lambert-Niclot S, Peytavin G, Duvivier C, et al. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother 2010; 54:4910-4913.
80. Barau C, Delaugerre C, Braun J, et al. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother 2010; 54:937-939.
81. Calcagno A, Bonora S, D'Avolio A, et al. Raltegravir penetration in seminal plasma of healthy volunteers. Antimicrob Agents Chemother 2010; 54:2744-2745.
82. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83:293-299.
83. Chakraborty H, Sen PK, Helms RW, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001; 15:621-627. (Pubitemid 32281358)
84. Brown K, Patterson KB, Malone S, et al. Antiretrovirals for prevention: maraviroc exposure in the semen and rectal tissue of healthy male volunteers after single and multiple dosing. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 611.
85. Tiraboschi JM, Curto J, Podzamczer D. Maraviroc levels in cerebrospinal fluid (CSF) and seminal plasma from HIV-infected pateints. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 114.
86. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732. (Pubitemid 41552605)
87. ClinicalTrials.gov. Phase IV, open label study in healthy male subjects to investigate the extent of darunavir/ritonavir and etravirine exposure in blood, seminal fluid, and rectal mucosal tissue following single and multiple dosing of darunavir/ritonavir and etravirine. (Updated 11 May 2011. Accessed 28 Sept 2010.) Available from http://clinicaltrials.gov/ct2/show/NCT00855088
88. ClinicalTrials.gov. Antiretroviral activity and tolerability of once daily etravirine in treatment-naive adults with HIV-1 infection (Updated 2 June 2011. Accessed 28 Sept 2010.) Available from http://clinicaltrials.gov/show/ NCT00959894
89. ClinicalTrials.gov. PrEP TMC278LA: safety, tolerability and pharmacokinetics of TMC278LA in HIV negative volunteers. (Updated 27 January 2011. Accessed 28 Sept 2010.) Available from http://clinicaltrials.gov/ct2/show/ NCT01275443
90. UNAIDS, WHO. AIDS epidemic update: November 2007. (Updated 25 November 2009. Accessed 28 Sept 2010.) Available from http://data.unaids.org/pub/Report/ 2009/JC1700-Epi-Update-2009-en.pdf
91. Tuomala RE, O'Driscoll PT, Bremer JW, et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis 2003; 187:375-384. (Pubitemid 36184578)
92. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-981. (Pubitemid 351652248)
93. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101. (Pubitemid 41233212)
94. Melo MG, Santos BR, De Cassia Lira R, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis 2008; 35:912-915.
95. Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV transmission under highly active antiretroviral therapy. Lancet 2008; 372:1806-1807.
96. Yeh RF, Rezk NL, Kashuba AD, et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother 2009; 53:2367-2374.
97. Patterson K, Jennings S, Falcon R, Mrus JM, Kashuba A. Darunavir, ritonavir and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother 2011; 55:1120-1122.
98. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46:719-725. (Pubitemid 351321556)
99. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007; 21:1899-1907. (Pubitemid 47329766)
100. Min SS, Corbett AH, Rezk N, et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004; 37:1577-1580. (Pubitemid 39658196)
101. Jones A, Talameh J, Patterson K, et al. First-dose and steady-state pharmacokinetics (PK) of raltegravir (RAL) in the genital tract (GT) of HIV uninfected women. 10th International Workshop on Clinical Pharmacology of HIV Therapy. 15-17 April 2009, Amsterdam, the Netherlands. Abstract O-06.
102. Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:546-553.
103. Fletcher CV, Acosta EP, Henry K, et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 1998; 64:331-338. (Pubitemid 28462294)
104. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16:551-560. (Pubitemid 34218850)
105. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006; 42:584-587. (Pubitemid 44162427)
106. Si-Mohamed A, Kazatchkine MD, Heard I, et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000; 182:112-122. (Pubitemid 30497795)
107. Launay O, Tod M, Louchahi K, et al. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother 2004; 48:632-634. (Pubitemid 38141731)
108. Bouley M, Briere C, Padoin C, Petitjean O, Tod M. Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography. Ther Drug Monit 2001; 23:56-60. (Pubitemid 32105966)
109. Else LJ, Lyons F, O'Shea S, et al. Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS 2011; 25:722-725.
110. Ivanovic J, Bellagamba R, Nicastri E, et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS 2010; 24:1083-1084.
111. Clavel C, Mandelbrot L, Marcelin AG, et al. Raltegravir concentrations in the cervicovaginal compartment exceed the median inhibitory concentration in HIV-1 infected women treated with a raltegravir-containing regimen: DIVA 01 Study. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 608.
112. Talameh JA, Rezk NL, Kashuba AD. Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:92-96.
113. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999; 179:871-882. (Pubitemid 29159332)
114. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358:1593-1601. (Pubitemid 33101909)
115. McClelland RS, Wang CC, Overbaugh J, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002; 16:2425-2430. (Pubitemid 35471690)
116. Patterson K, Prince H, Kraft M, et al. Exposure of extracellular and intracellular tenofovir and emtricitabine in mucosal tissues after a single fixed dose of TDF/FTC: implications for pre-exposure HIV prophylaxis (PrEP). XVII International Aids Conference. 18-23 July 2010, Vienna, Austria. Abstract THB50305.
117. Owen DH, Katz DF. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl 2005; 26:459-469. (Pubitemid 40847857)
118. Pfau A, Perlberg S, Shapira A. The pH of the prostatic fluid in health and disease: implications of treatment in chronic bacterial prostatitis. J Urol 1978; 119:384-387. (Pubitemid 8337781)
119. Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19:825-835. (Pubitemid 37215138)
120. Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther 2010; 88:598-609.
121. Salas Herrera IG, Pearson RM, Turner P. Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus. Hum Exp Toxicol 1991; 10:137-139.
122. Lizana J, Blad E. Immunonephelometry of specific proteins in human seminal plasma. Clin Chem 1983; 29:618-623. (Pubitemid 13109695)
123. Panidis D, Rousso D, Panidou E, Asseo P. Orosomucoid levels in the seminal plasma or fertile and infertile men. Arch Androl 1993; 30:161-164.
124. Cao YPT, Bakshi RP, Fuchs EJ, et al. A novel method demonstrating protein unbound indinavir concentration in seminal plasma. Clin Pharmacol Ther 2007; 81:S99.
125. Avery LB, Bakshi RP, Cao Y, Hendrix CW. The male genital tract is not a pharmacological sanctuary from efavirenz. Clin Pharmacol Ther 2011; 90:151-156.
126. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84:7735-7738.
127. Corden-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989; 86:695-698. (Pubitemid 19037807)
128. Holash JA, Harik SI, Perry G, Stewart PA. Barrier properties of testis microvessels. Proc Natl Acad Sci U S A 1993; 90:11069-11073. (Pubitemid 23354370)
129. Finstad CL, Saigo PE, Rubin SC, et al. Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions. J Histochem Cytochem 1990; 38:1677-1681. (Pubitemid 20346978)
130. Stewart PA, Beliveau R, Rogers KA. Cellular localization of P-glycoprotein in brain versus gonadal capillaries. J Histochem Cytochem 1996; 44:679-685. (Pubitemid 26240775)
131. Bart J, Hollema H, Groen HJ, et al. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 2004; 40:2064-2070. (Pubitemid 39165539)
132. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28:655-660. (Pubitemid 30390404)
133. Kawai K, Sakurai M, Sakai T, et al. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett 2000; 150:147-153. (Pubitemid 30125848)
134. Schummer B, Siegsmund M, Steidler A, Toktomambetova L, Kohrmann KU, Alken P. Expression of the gene for the multidrug resistance-associated protein in human prostate tissue. Urol Res 1999; 27:164-168. (Pubitemid 29287593)
135. Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis 2000; 182:758-765.